IPP Bureau
Sucralose safe to use in small doses; reveals MDRF study
By IPP Bureau - August 07, 2024
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
Aster DM Healthcare launches Pediatric & Geriatric Emergency Departments at Aster MIMS, Calicut
By IPP Bureau - August 07, 2024
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
UK Relonchem receives marketing authorization for Levonorgestrel 1.5 mg Tablets
By IPP Bureau - August 06, 2024
Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA
Narayana Hrudayalaya posts Q1 FY25 consolidated PAT higher at Rs. 201.37 Cr
By IPP Bureau - August 06, 2024
Narayana Hrudayalaya has reported total income of Rs. 1364.44 crores during the period ended June 30, 2024
Lupin completes successful Phase 3 trials for Lucentis biosimilar
By IPP Bureau - August 06, 2024
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Lupin receives USFDA approval for Prednisolone Acetate Ophthalmic Suspension USP
By IPP Bureau - August 06, 2024
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
OneSource and BRL ink technology licensing agreement to deliver high-concentration biologics subcutaneously
By IPP Bureau - August 06, 2024
Revolutionary technology will further boost OneSource’s scientific services offerings
Vijaya Diagnostic Centre reports Q1 FY25 consolidated PAT at Rs. 31.34 Cr
By IPP Bureau - August 06, 2024
Vijaya Diagnostic Centre has reported total income of Rs. 159.78 crores during the quarter ended June 30, 2024
Indraprastha Medical Corporation posts Q1 FY25 PAT at Rs. 44.77 Cr
By IPP Bureau - August 06, 2024
Indraprastha Medical Corporation has reported total income of Rs. 352.98 crores during the quarter ended June 30, 2024
Cupid post Q1 FY25 profit at Rs. 8.25 Cr
By IPP Bureau - August 06, 2024
Cupid Ltd has reported total income of Rs. 44.02 crores during the quarter ended June 30, 2024
SMS Pharmaceuticals reports Q1 FY25 consolidated PAT at Rs. 16.48 Cr
By IPP Bureau - August 06, 2024
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
Aurobindo Pharma receives USFDA approval for Estradiol Vaginal Inserts USP, 10 mcg
By IPP Bureau - August 06, 2024
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Roche closes acquisition of LumiraDx’s Point of Care technology
By IPP Bureau - August 05, 2024
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
Divis Laboratories reports Q1 FY25 consolidated PAT at Rs. 430 Cr
By IPP Bureau - August 05, 2024
Divis Laboratories has reported total income of Rs. 2,197 crores during the period ended June 30, 2024
Finerenone meets primary endpoint in Phase III FINEARTS-HF cardiovascular study
By IPP Bureau - August 05, 2024
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
